← All trials
NCT01778634
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2013
- Primary completion
- Dec 1, 2019
- Completion date
- Dec 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MarylandLead sponsor
- Mercy Medical CenterCollaborator
- Johns Hopkins UniversityCollaborator
- University of VirginiaCollaborator
- Thomas Jefferson UniversityCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- University of VirginiaOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- Mercy Medical CenterOverall official - principal investigator
- University of MarylandSponsor investigator
- University of MarylandStudy chair
- National Institutes of Health (NIH)Collaborator
- University of Alabama, BirminghamOverall official - principal investigator
- University of Alabama, BirminghamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.